40 research outputs found
QCD and strongly coupled gauge theories : challenges and perspectives
We highlight the progress, current status, and open challenges of QCD-driven physics, in theory and in experiment. We discuss how the strong interaction is intimately connected to a broad sweep of physical problems, in settings ranging from astrophysics and cosmology to strongly coupled, complex systems in particle and condensed-matter physics, as well as to searches for physics beyond the Standard Model. We also discuss how success in describing the strong interaction impacts other fields, and, in turn, how such subjects can impact studies of the strong interaction. In the course of the work we offer a perspective on the many research streams which flow into and out of QCD, as well as a vision for future developments.Peer reviewe
Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery.
INTRODUCTION: Postoperative morbidity and mortality in older patients with comorbidities undergoing gastrointestinal surgery are a major burden on healthcare systems. Infections after surgery are common in such patients, prolonging hospitalisation and reducing postoperative short-term and long-term survival. Optimal management of perioperative intravenous fluids and inotropic drugs may reduce infection rates and improve outcomes from surgery. Previous small trials of cardiac-output-guided haemodynamic therapy algorithms suggested a modest reduction in postoperative morbidity. A large definitive trial is needed to confirm or refute this and inform widespread clinical practice. METHODS: The Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial is a multicentre, international, parallel group, open, randomised controlled trial. 2502 high-risk patients undergoing major elective gastrointestinal surgery will be randomly allocated in a 1:1 ratio using minimisation to minimally invasive cardiac output monitoring to guide protocolised administration of intravenous fluid combined with low-dose inotrope infusion, or usual care. The trial intervention will be carried out during and for 4âhours after surgery. The primary outcome is postoperative infection of Clavien-Dindo grade II or higher within 30 days of randomisation. Participants and those delivering the intervention will not be blinded to treatment allocation; however, outcome assessors will be blinded when feasible. Participant recruitment started in January 2017 and is scheduled to last 3âyears, within 50 hospitals worldwide. ETHICS/DISSEMINATION: The OPTIMISE II trial has been approved by the UK National Research Ethics Service and has been approved by responsible ethics committees in all participating countries. The findings will be disseminated through publication in a widely accessible peer-reviewed scientific journal. TRIAL REGISTRATION NUMBER: ISRCTN39653756.The OPTIMISE II trial is supported by Edwards Lifesciences (Irvine, CA) and the UK National Institute for Health Research through RMPâs NIHR Professorship
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study
Background Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2â11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75â1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58â1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91â1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70â1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11â0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50â0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38â0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45â0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health
Evaluation of appendicitis risk prediction models in adults with suspected appendicitis
Background
Appendicitis is the most common general surgical emergency worldwide, but its diagnosis remains challenging. The aim of this study was to determine whether existing risk prediction models can reliably identify patients presenting to hospital in the UK with acute right iliac fossa (RIF) pain who are at low risk of appendicitis.
Methods
A systematic search was completed to identify all existing appendicitis risk prediction models. Models were validated using UK data from an international prospective cohort study that captured consecutive patients aged 16â45âyears presenting to hospital with acute RIF in March to June 2017. The main outcome was best achievable model specificity (proportion of patients who did not have appendicitis correctly classified as low risk) whilst maintaining a failure rate below 5 per cent (proportion of patients identified as low risk who actually had appendicitis).
Results
Some 5345 patients across 154 UK hospitals were identified, of which twoâthirds (3613 of 5345, 67·6 per cent) were women. Women were more than twice as likely to undergo surgery with removal of a histologically normal appendix (272 of 964, 28·2 per cent) than men (120 of 993, 12·1 per cent) (relative risk 2·33, 95 per cent c.i. 1·92 to 2·84; Pâ<â0·001). Of 15 validated risk prediction models, the Adult Appendicitis Score performed best (cutâoff score 8 or less, specificity 63·1 per cent, failure rate 3·7 per cent). The Appendicitis Inflammatory Response Score performed best for men (cutâoff score 2 or less, specificity 24·7 per cent, failure rate 2·4 per cent).
Conclusion
Women in the UK had a disproportionate risk of admission without surgical intervention and had high rates of normal appendicectomy. Risk prediction models to support shared decisionâmaking by identifying adults in the UK at low risk of appendicitis were identified
Effect of nitrogen doses on disease severity and watermelon yield InfluĂȘncia de doses de nitrogĂȘnio na severidade de doenças e na produtividade da melancia
Nitrogen fertilization is an important step for watermelon (Citrullus lanatus) production due to its influence over yield, fruit quality, and disease severity. Currently, the gummy stem blight (Didymella bryoniae) and the downy mildew (Pseudoperonospora cubensis) can be taken as the most important watermelon diseases, since they impose severe impairment to the crop. Furthermore, studies focusing on plant responses to nitrogen fertilization regarding fruit yield and quality, and disease resistance are rare. Hence, the present study aimed at evaluating the effect of nitrogen doses on fruit yield and quality, and on disease prevalence in watermelon. Two experiments were carried out at the Universidade Federal de Tocantins, employing sprinkler irrigation, in an area previously used to grow watermelon. The experimental design was blocks at random, with five treatments (N doses, applied twice as side-dressing, in kg ha-1, as follows: T1= control treatment without N, T2= 20, T3= 40, T4= 80, and T5= 120), and four replications. Urea (45% N) was used as the N source. In the first assay, the highest fruit yield and average weight were observed when 40 kg ha-1 of N were applied. The highest severity of the gummy stem blight was observed when the highest nitrogen doses were applied (80 and 120 kg ha-1). In the second assay, the highest severity levels of the gummy stem blight, as well as of mildew, were observed again when N doses were the highest (80 and 120 kg ha-1). The lowest severity levels for both diseases were observed in the control treatment.<br>A adubação nitrogenada Ă© importante para a cultura da melancia (Citrullus lanatus) por afetar diretamente a produtividade, a qualidade dos frutos e a severidade de doenças. Atualmente, o crestamento gomoso (Didymella bryoniae) e o mĂldio (Pseudoperonospora cubensis) podem ser consideradas as doenças mais importantes da melancia devido aos prejuĂzos que podem causar na lavoura. Estudos envolvendo a aplicação de doses de nitrogĂȘnio e seus efeitos na produtividade, qualidade de frutos e manifestação de doenças sĂŁo escassos. Desta forma, o presente trabalho teve como objetivo avaliar diferentes doses de nitrogĂȘnio e seus efeitos na produtividade, caracterĂsticas dos frutos e na prevalĂȘncia de doenças da melancieira. Foram conduzidos dois ensaios na Universidade Federal do Tocantins, sob irrigação por aspersĂŁo, em ĂĄrea anteriormente cultivada com melancia. Foi utilizado o delineamento experimental de blocos ao acaso, com cinco tratamentos (doses de nitrogĂȘnio, aplicados em duas vezes em cobertura, em kg ha-1, sendo T1= testemunha sem nitrogĂȘnio em cobertura, T2= 20, T3= 40, T4= 80 e T5= 120) e quatro repetiçÔes. A urĂ©ia foi utilizada como fonte de nitrogĂȘnio (45% de N). No ensaio I, verificou-se maior produtividade e maior peso mĂ©dio de frutos no tratamento que recebeu 40 kg ha-1. NĂveis mais altos de severidade do crestamento gomoso foram verificados nos tratamentos que receberam maiores dosagens de nitrogĂȘnio (80 e 120 kg). No ensaio II, nos tratamentos com 80 e 120 kg ha de N foram observados os nĂveis mais altos de mĂldio e crestamento gomoso. Menores nĂveis dessas doenças foram verificados no tratamento testemunha